New York State Common Retirement Fund Purchases 37,133 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

New York State Common Retirement Fund lifted its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 14.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 297,448 shares of the medical equipment provider's stock after buying an additional 37,133 shares during the quarter. New York State Common Retirement Fund owned about 0.63% of BioLife Solutions worth $6,794,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in BioLife Solutions by 8.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 346,421 shares of the medical equipment provider's stock worth $8,993,000 after purchasing an additional 26,462 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at approximately $638,000. Intech Investment Management LLC raised its position in shares of BioLife Solutions by 164.6% in the fourth quarter. Intech Investment Management LLC now owns 26,985 shares of the medical equipment provider's stock valued at $701,000 after buying an additional 16,785 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of BioLife Solutions in the fourth quarter valued at approximately $201,000. Finally, Sei Investments Co. grew its position in BioLife Solutions by 7.4% during the fourth quarter. Sei Investments Co. now owns 117,452 shares of the medical equipment provider's stock worth $3,049,000 after buying an additional 8,096 shares in the last quarter. Institutional investors own 93.24% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on BLFS. Wall Street Zen cut BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $31.17.

Insider Buying and Selling at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the completion of the transaction, the insider directly owned 7,707,165 shares in the company, valued at $183,430,527. This represents a 11.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 1,007,716 shares of company stock valued at $23,975,998. Company insiders own 2.20% of the company's stock.

BioLife Solutions Stock Down 2.8%

NASDAQ BLFS opened at $20.83 on Monday. The business has a fifty day moving average price of $22.17 and a two-hundred day moving average price of $24.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.73 and a quick ratio of 3.74. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.55. The stock has a market capitalization of $996.40 million, a PE ratio of -71.83 and a beta of 1.79.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. Equities analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Want to see what other hedge funds are holding BLFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.